Authors:

Laria Santo De Sousa

State University of Bahia, Brazil

Abstract:

Background: The best management of HBsAg-negative, anti-HBc-positive patients United Nations agency receive immunological disorder remains unclarified. we tend to consistently reviewed the offered knowledge on potential predictors of the danger of hepatitis B virus (HBV) reactivation in such patients. Methods: A literature search known fifty five studies with 3640 HBsAg-negative, anti-HBc-positive patients United Nations agency received immunological disorder regimens. Results: HBV reactivation was reportable in 236 (6.5%) patients. The pooled HBV reactivation rates failed to dissent between patients with detectable or undetectable HBV desoxyribonucleic acid in studies with hematologic diseases or regimens containing rituximab, however it had been higher in patients with detectable than in those with undetectable HBV desoxyribonucleic acid United Nations agency were taking rituximab-free regimens (14% vs. 2.6%; risk quantitative relation [RR] twelve.67, ninety fifth CI: 95%CI a pair of.39-67.04, P=0.003) or had non-hematological diseases, though the latter wasn’t confirmed by sensitivity analysis (RR eight.80, 95%CI 0.71-109.00, P=0.09). The pooled HBV reactivation rates were lower in patients with positive than in those with negative anti-HBs in studies with hematologic (7.1% vs. 21.8%; RR 0.29, 95%CI 0.19-0.46, P.

Keywords:
Chronic hepatitis B infection, antiviral therapy, lamivudine, entecavir, tenofovir.

Citation:

Laria Santo de Sousa. A systematic analysis of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients on immunosuppressive therapy. Japanese Journal of Gastroenterology 2022.